# Integrin  $\boldsymbol{\beta}\nu$ -mediated Phagocytosis of Apoptotic Cells in *Drosophila* **Embryos\***□**<sup>S</sup>**

Received for publication, November 19, 2010, and in revised form, April 25, 2011 Published, JBC Papers in Press, May 18, 2011, DOI 10.1074/jbc.M110.204503

Kaz Nagaosa<sup>द</sup>, Ryo Okada<sup>‡</sup>, Saori Nonaka<sup>‡</sup>, Kazuki Takeuchi<sup>§</sup>, Yu Fujita<sup>‡</sup>, Tomoyuki Miyasaka<sup>¶</sup>, Junko Manaka<sup>‡</sup>, **István Ando<sup>||</sup>, and Yoshinobu Nakanishi**<sup>द1</sup>

*From the* ‡ *Graduate School of Medical Science,* § *Graduate School of Natural Science and Technology, and* ¶ *School of Pharmacy, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan and the Institute of Genetics, Biological Research Center of Hungarian Academy of Sciences, P. O. Box 521, H-6701 Szeged, Hungary*

**To identify molecules that play roles in the clearance of apoptotic cells by** *Drosophila* **phagocytes, we examined a series of monoclonal antibodies raised against larval hemocytes for effects on phagocytosis** *in vitro***. One antibody that inhibited phagocytosis recognized terribly reduced optic lobes (Trol), a core protein of the perlecan-type proteoglycan, and the level of phagocytosis in embryos of a Trol-lacking fly line was lower than in a control line. The treatment of a hemocyte cell line with a recombinant Trol protein containing the amino acid sequence RGD augmented the phosphorylation of focal adhesion kinase, a** hallmark of integrin activation. A loss of integrin  $\beta\nu$ , one of the **two**  $β$  subunits of *Drosophila* integrin, brought about a reduc**tion in the level of apoptotic cell clearance in embryos. The pres**ence of integrin  $\beta \nu$  at the surface of embryonic hemocytes was confirmed, and forced expression of integrin  $\boldsymbol{\beta}\nu$  in hemocytes of an integrin  $\beta \nu$ -lacking fly line recovered the defective pheno**type of phagocytosis. Finally, the level of phagocytosis in a fly** line that lacks both integrin  $\boldsymbol{\beta}\nu$  and Draper, another receptor **required for the phagocytosis of apoptotic cells, was lower than that in a fly line lacking either protein. We suggest that integrin**  $\beta\nu$  serves as a phagocytosis receptor responsible for the clear**ance of apoptotic cells in** *Drosophila***, independent of Draper.**

Phagocytic elimination of dead or dying cells plays an important role in animal development and tissue homeostasis (1–3). Phagocytes recognize target cells undergoing apoptosis through the specific binding of phagocytosis receptors to phagocytosis markers or eat-me signals (4, 5). It is therefore essential to identify such molecules to fully understand the mechanism and consequences of this biological event. There are two partly overlapping signaling pathways for the induction of corpse clearance in the nematode *Caenorhabditis elegans* (6–9), suggesting the presence of two distinct phagocytosis receptors. One receptor is CED-1, a single-path membrane protein with atypical EGF-like repeats in its extracellular region (10). There

are counterparts of CED-1 in other species (11), Draper in *Drosophila* (12, 13), Jedi in mice (14), and MEGF10 in humans (15), the involvement of which in the phagocytosis of apoptotic cells has been reported. However, the other receptor presumably conserved among species remains to be identified. Recently, two membrane proteins, Frizzled (16) and INA-1 (17), were reported to be involved in phagocytosis in *C. elegans*, and they are strong candidates for the "second" receptor.

We and other investigators previously showed that Draper, a *Drosophila* homologue of CED-1, is responsible for the phagocytosis of apoptotic cells by hemocytes and glia (12, 13). A loss of Draper expression decreased the level of phagocytosis in embryos by only about one-third (18), suggesting the existence of another mechanism of phagocytosis, presumably one involving the second receptor. A pioneer study of Franc *et al.* (19, 20) has identified a phagocytosis receptor called Croquemort, but this receptor has no structural similarity to Frizzled or INA-1. To search for the second receptor in *Drosophila*, we decided to employ a comprehensive strategy. In the present study, we screened a series of monoclonal antibodies that had been raised against larval hemocytes for effects on phagocytosis and found integrin as a likely candidate.

#### **EXPERIMENTAL PROCEDURES**

*Antibodies*—The generation of the antibody recognizing Croquemort, a member of the CD36 superfamily expressed specifically at the surface of *Drosophila* hemocytes (19, 20), was reported previously (13), and it was used to identify hemocytes in dispersed embryonic cells. The monoclonal antibodies raised against *Drosophila* larval hemocytes were generated as described previously (21). Briefly, BALB/c mice were immunized with hemocytes of late third instar larvae, and spleen cells were fused with *SP2*/*O* myeloma cells. Culture supernatants of the resulting hybridoma were immunochemically screened for the binding to larval hemocytes, and the selected hybridomas were subcloned. The anti-integrin  $\beta\nu$  antibodies were raised by immunizing rats with an extracellular region (amino acid positions 650–722 with the amino terminus numbered 1) and intracellular region (positions 753–799) of integrin  $\beta\nu$  that had been expressed in *Escherichia coli* as proteins fused to GST and purified to homogeneity and used for immunocytochemistry and Western blotting, respectively. The antigen specificity of these two anti-integrin  $\beta\nu$  antibodies was confirmed [\(supplemental](http://www.jbc.org/cgi/content/full/M110.204503/DC1) [Fig. 1,](http://www.jbc.org/cgi/content/full/M110.204503/DC1) *A* and *B*). The antibody against FAK56, a *Drosophila*



<sup>\*</sup> This study was supported by Grants-in-Aidfor Scientific Research 19370051, 22370049, and 22657033 from the Japan Society for the Promotion of Science (to Y. N.), the Hungarian National Research Fund Országos Tudomónyos Kutatási Alap (National Scientific Research Fund) Grant NK78024 (to

I. A.), and a grant from the Fuji Foundation for Protein Research (to K. N.).<br>
<sup>1</sup> The on-line version of this article (available at http://www.jbc.org) contains [supplemental Figs. 1–3 and Table 1.](http://www.jbc.org/cgi/content/full/M110.204503/DC1)<br><sup>1</sup> To whom correspondence should be addressed: Shizenken, Kakuma-machi,

Kanazawa, Ishikawa 920-1192, Japan. Fax: 81-76-234-4481; E-mail: nakanaka@p.kanazawa-u.ac.jp.

counterpart of mammalian focal adhesion kinase  $(FAK)<sup>2</sup>$  was produced by immunizing rats with a portion of FAK56 (positions 881–1200) that had been expressed in *E. coli* as a GSTfused protein and purified to homogeneity. The anti-phosphorylated (at tyrosine 397) human FAK polyclonal antibody was purchased from Abcam. The antigen specificity of anti-FAK56 and anti-phospho-FAK antibodies was confirmed [\(supplemen](http://www.jbc.org/cgi/content/full/M110.204503/DC1)[tal Figs. 1](http://www.jbc.org/cgi/content/full/M110.204503/DC1)*C* and 2). The anti-GST monoclonal antibody was purchased from Millipore.

*Fly Stocks and Cell Culture*—The following fly lines were used in this study: *w1118* (Bloomington *Drosophila* Stock Center, Indiana University, Bloomington, IN), *trolnull* (22), *mys<sup>1</sup>* (23), *mysXG43* (23), *betaInt-nu<sup>1</sup>* (24), *betaInt-nu<sup>2</sup>* (24),*srpHemo-GAL4 UAS-srcEGFP* (25), *drpr<sup>5</sup>* (12), *UAS-Crk-IR* (Transformant ID 19061, Vienna *Drosophila* RNAi Center, Vienna, Austria), *UAS-Crk-IR* (Transformant ID 106498, Vienna *Drosophila* RNAi Center), *UAS-mbc-IR* (Transformant ID 16044, Vienna *Drosophila* RNAi Center), and *Act5C-GAL4/CyO* (*Drosophila* Genetic Resource Center (DGRC) number 107727, DGRC, Kyoto, Japan). We established fly lines containing an extra *betaInt-nu* to be expressed with the GAL4-UAS system using the entire coding region of *betaInt-nu* cDNA obtained from  $w^{1118}$  and the vector pUAST (26), and one line carrying the transgene on the third chromosome was intercrossed with the fly lines *betaInt-nu<sup>2</sup>* and/or *srpHemo-GAL4 UAS-srcEGFP* (for hemocyte-specific expression) and used in the experiments. Other fly lines used were generated through mating of the existing lines. Genotypes of the fly lines analyzed are shown in the corresponding figure legends. The cell lines l(2)mbn, established from larval hemocytes, and embryonic-cell derived S2 were maintained at 25 °C with Schneider's *Drosophila* medium (Invitrogen) as described previously (13). l(2)mbn cells were incubated with 20-hydroxyecdysone (Sigma-Aldrich) (1  $\mu$ <sub>M</sub>) for 48 h before being used in an assay for phagocytosis. To induce apoptosis, S2 cells were incubated in the presence of cycloheximide (Sigma-Aldrich) (1.5  $\mu$ g/ml) for 24 h as described previously (13).

*Assays for Phagocytosis*—Phagocytosis reactions*in vitro* with l(2)mbn cells as phagocytes and S2 cells, which had been treated with cycloheximide and surface-labeled with biotin, as targets were carried out at 25 °C for 2 h as described previously (13). To examine the effect of the monoclonal antibodies, 0.2 ml of the culture supernatant of hybridoma cells (RPMI 1640 medium containing 5% (v/v) FBS) was dialyzed against PBS, mixed with 0.1 ml of the medium, and added to the mixture of phagocytes and target cells. An RNAi experiment *in vitro* was conducted essentially as described previously (13). Double-stranded RNA corresponding to the region between nucleotide positions 5684 and 6203 (with the transcription start site numbered 1) of terribly reduced optic lobes (Trol) mRNA (transcript variant C) or the region between nucleotide positions 1322 and 2463 (with the transcription start site numbered 1) of Draper mRNA was included in the phagocytosis reaction at  $25-50 \mu$ g/ml. An analysis of phagocytosis with dispersed embryonic cells was conducted according to the procedures described in our previous

# *Integrin-mediated Phagocytosis in Drosophila*

study with modifications (13); results obtained in this assay for phagocytosis were shown to be consistent with those from the analysis of whole embryos (18). *Drosophila* embryos were dechorionated, and those at stage 16 were collected. About 50 embryos were homogenized in the presence of collagenase  $(2.5\%$  (w/v)) and treated with trypsin  $(2.5\%$  (w/v)), and the homogenates were filtrated through a membrane (BD Falcon cell strainer, BD Biosciences). Cells recovered in the filtrates were mounted on silane-coated glass slides, treated successively with paraformaldehyde, methanol, and Triton X-100, and incubated with swine serum  $(5\% (v/v))$  for blocking. The fixed and blocked embryonic cells were cytochemically analyzed with the anti-Croquemort antibody to identify hemocytes and by TUNEL (Millipore) to identify apoptotic cells, and cells positive for both reactions were considered embryonic hemocytes that had phagocytosed apoptotic cells. A microscopic field containing 100 or more embryonic cells that were positive for Croquemort expression was examined for the number of TUNEL-stained cells, and a field containing 100 or more total embryonic cells was examined for the ratios of Croquemortexpressing hemocytes and TUNEL-positive apoptotic cells. A mean of the results with five microscopic fields was obtained in each experiment.

*Immunocytochemistry*—For immunocytochemical detection of Trol at the surface of ecdysone-treated l(2)mbn cells, cells smeared on silane-coated glass slides were incubated with purified #16 immunoglobulin or normal mouse IgG (50  $\mu$ g/ml) on ice for 45 min, washed with PBS containing 0.1% (w/v) BSA, and reacted with biotin-labeled anti-mouse IgG antibody (Zymed Laboratories Inc.). The samples were washed, supplemented with FITC-conjugated avidin D (Vector Laboratories), washed again, and examined by fluorescence/phase-contrast microscopy. For the detection of GST-fused Trol proteins bound to the surface of l(2)mbn cells, cells were incubated with GST-fused proteins (5  $\mu$ M) at 4 °C for 1 h, washed, and incubated with PBS containing 0.1% BSA. The cells were then successively treated with anti-GST antibody and biotin-labeled secondary antibody, washed, treated with Alexa Fluor 488-labeled streptavidin (Molecular Probes), and examined by fluorescence/phase-contrast microscopy. For the detection of integrin  $\beta \nu$ , l(2)mbn cells or dispersed cells of stage-16 embryos were smeared on silane-coated glass slides, incubated with 1% (w/v) blocking reagent (Roche Applied Science), reacted with the anti-integrin  $\beta\nu$  antibody (rat antiserum) or preimmune rat serum on ice for 15 min, and washed with PBS. They were then reacted with a biotin-labeled anti-rat IgG antibody (Vector Laboratories), washed with PBS, supplemented with streptavidin-conjugated Alexa Fluor 546 (Molecular Probes), and washed. The final samples were examined by fluorescence/ phase-contrast microscopy.

*Assay for Trol-induced Phosphorylation of FAK56*—Recombinant Trol proteins corresponding to a portion of Trol (amino acid positions 1948–2147 or 2846–3035) were expressed in *E. coli* as a protein fused to GST and purified to homogeneity. PBS containing a Trol protein  $(0.2 \mu)$  or GST used as a negative control was incubated in a culture container at 4 °C overnight. The dishes were washed with PBS, incubated with 2% BSA at 37 °C for 2 h, and washed with PBS. l(2)mbn cells that



 $2$  The abbreviations used are: FAK, focal adhesion kinase; Trol, terribly reduced optic lobes.

had been maintained with an FBS-free medium for 2 h were added to the protein-coated dishes, incubated at 25 °C for 2 h, and lysed with buffer consisting of 10 mm Tris-HCl (pH 7.5), 1% (v/v) Nonidet P-40, 0.1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 0.15  $\text{M}$  NaCl, 1 mM EDTA, 1% (v/v) protease inhibitor mixture (Sigma-Aldrich), and 1% (v/v) phosphatase inhibitor mixture (Sigma-Aldrich). The lysates were analyzed by Western blotting with the anti-FAK56 antibody or anti-phospho-FAK antibody.

*Other Methods*—Semiquantitative RT-PCR was done according to a standard protocol using total RNA extracted from l(2)mbn cells as a template in RT. We optimized conditions for PCR, *i.e.* annealing temperature, cycles for DNA synthesis, and the amount of cDNA template, so that amplification occurred at an exponential phase. Western blotting of lysates of cultured cells was done as described previously (13). Flies at various developmental stages were homogenized in a buffer consisting of 50 mm Tris-HCl (pH 7.5), 0.15 m NaCl, 5 mm MgCl<sub>2</sub>, 0.1% (v/v) Triton X-100, 0.1% Nonidet P-40, and 10% (v/v) glycerol, and the resulting lysates were analyzed by Western blotting as for cultured cells. For the analysis of the growth rate of *Drosophila*, 100–200 embryos in a vial were developed at 24 °C, and the number of adult flies that emerged was determined each day.

*Data Processing and Statistical Analysis*—Data from quantitative analyses are expressed as the mean  $\pm$  S.D. of the results from at least three independent experiments, unless otherwise stated in the text. Other data are representative of at least three independent experiments that yielded similar results. Statistical analyses were performed using Student's*t*test. Values of *p* 0.05 were considered significant and are indicated in the figures.

#### **RESULTS**

*Identification of Trol Required for Phagocytosis of Apoptotic Cells by Drosophila Phagocytes*—To identify molecules required for *Drosophila* hemocytes to engulf apoptotic cells, we tested a series of monoclonal antibodies, which had been generated by immunizing mice with larval hemocytes, for effects on the phagocytosis of apoptotic S2 cells by l(2)mbn cells, a cell line derived from larval hemocytes. Of 82 hybridoma clones (operationally renumbered 1– 82) analyzed, 16 were found to produce culture supernatants that had inhibitory or stimulatory effect on phagocytosis with statistical significance, whereas the others did not influence phagocytosis (Fig. 1*A*). We then examined immunoglobulin prepared from the culture supernatants of five hybridoma clones that had a more prominent effect than the others and found that the #16 and #43 antibodies inhibited phagocytosis (Fig. 1*B*). We further characterized the #16 antibody because the inhibition provided by the #43 antibody was only marginal.

Results from a phage-display analysis revealed a cognate antigen for the #16 antibody to be a core protein of the perlecan-type proteoglycan (27) encoded by *trol* (22). When l(2)mbn cells were immunocytochemically analyzed with the #16 antibody under conditions without membrane permeabilization, they were found to be bound by the antibody but not by the control IgG (Fig. 1*C*), indicating the presence of Trol at the cell

surface. We next examined the phagocytosis of apoptotic cells in embryos of flies lacking Trol. Embryonic cells were dispersed and analyzed simultaneously by immunocytochemistry with an anti-Croquemort antibody and by TUNEL. We considered cells positive for both reactions as embryonic hemocytes that had phagocytosed apoptotic cells (Fig. 1*D*, *top panels*), and the results showed that the level of phagocytosis in Trol-lacking flies was lower than in a control fly line (Fig. 1*D*, *bottom panels*). We previously identified Draper as a phagocytosis receptor responsible for the elimination of apoptotic cells by hemocytes and glia in *Drosophila* embryos (13). We thus examined how Trol functionally relates to Draper. For this purpose, l(2)mbn cells were treated with double-stranded RNA with the mRNA sequence of Trol or Draper before they were used in an assay for phagocytosis. Effectiveness of the RNAi-mediated reduction of each mRNA was confirmed by RT-PCR (Fig. 1*E*, *bottom panels*). Treatment with either double-stranded RNA brought about a reduction in the phagocytic activity of l(2)mbn cells, and that with a mixture of the two RNA sequences further decreased the level of phagocytosis (Fig. 1*E*, *top panels*). These results suggested that Trol and Draper function in l(2)mbn cells independently in the phagocytosis of apoptotic cells. All the above results collectively indicated that Trol, a core protein of *Drosophila* perlecan, is required for the effective phagocytosis of apoptotic cells by *Drosophila* embryonic hemocytes.

*Involvement of Integrin βv in the Phagocytosis of Apoptotic Cells by Drosophila Hemocytes*—The amino acid sequence RGD, a motif conserved among ligands for some groups of integrin (28), repeats three times in Trol (Fig. 2*A*), suggesting the involvement of integrin in the action of Trol. The RGD motif evokes an increase in the level of the phosphorylated form of FAK in integrin-expressing cells, and this event is considered a hallmark of activation of the RGD-binding integrin (29). We thus examined whether treatment with the RGD-containing Trol protein augments the phosphorylation of FAK in l(2)mbn cells. To do this, an antibody recognizing the phosphorylated form of mammalian FAK was first tested to see whether it detects phosphorylated FAK56, a *Drosophila*-type FAK (30– 32). When whole-cell lysates of l(2)mbn were successively analyzed by immunoprecipitation and Western blotting, the signal corresponding to FAK56 was seen with the anti-phospho-FAK antibody in the sample after immunoprecipitation with the anti-FAK56 antibody but not with normal rat serum [\(supple](http://www.jbc.org/cgi/content/full/M110.204503/DC1)[mental Fig. 2](http://www.jbc.org/cgi/content/full/M110.204503/DC1)*A*). Furthermore, the signals in Western blotting with the anti-phospho-FAK antibody disappeared after treating membranes containing transferred proteins with alkaline phosphatase, whereas the signal detected with the anti-FAK56 antibody was almost unaffected [\(supplemental Fig. 2](http://www.jbc.org/cgi/content/full/M110.204503/DC1)*B*). These results indicated that the phosphorylated form of *Drosophila* FAK is detectable by Western blotting with the antibody that recognizes the phosphorylated form of mammalian FAK. We first tested whether two Trol proteins containing one of the three RGD motifs (Fig. 2*A*) bind to l(2)mbn cells. The cells were incubated with GST-fused Trol proteins or GST alone used as a negative control, washed, and immunocytochemically analyzed with anti-GST antibody. The results showed that either Trol protein, but not GST alone, binds to l(2)mbn cells (Fig. 2*B*, *top panels*).We then examined the effect of the Trol proteins on the





Culture supernatants (clone #)

FIGURE 1. **Identification of Trol that plays a role in the phagocytosis of apoptotic cells by** *Drosophila* **hemocytes.** *A*, an assay for phagocytosis was conducted with ecdysone-treated l(2)mbn cells as phagocytes and apoptotic S2 cells as targets in the presence and absence of culture supernatants of the indicated hybridoma clones producing monoclonal antibodies raised against larval hemocytes. The ratio of l(2)mbn cells that had accomplished phagocytosis is shown. Significance is *versus none*. Data from one experiment are presented (S.D. are from data with four microscopic fields). *B*, the same assay as in *A* was conducted in the presence of immunoglobulin prepared from culture supernatants of the indicated hybridoma clones or normal mouse IgG (2  $\mu$ g/ml). The ratio of l(2)mbn cells that had accomplished phagocytosis is shown. Significance is *versus* control IgG. Data from one of two independent experiments with similar results are presented (S.D. are from data with six microscopic fields). *C*, ecdysone-treated l(2)mbn cells were subjected to immunocytochemistry with the #16 immunoglobulin or normal rat IgG as a negative control under membrane-nonpermeabilizing conditions. Phase-contrast and fluorescence micrographs of the same fields are shown. Scale bar, 20  $\mu$ m. D, phagocytosis of apoptotic cells was examined with dispersed embryonic cells of the indicated fly lines. Embryonic cells were cytochemically analyzed with an anti-Croquemort (*CRQ*) antibody (signals seen in *purple*) and by TUNEL (signals seen in *brown*) (*top*). *Scale bar*, 5m. The ratio of hemocytes that had accomplished phagocytosis is shown (*bottom*). The genotype of*trolnull* is*trolnull FRT101/Y*. *E*, l(2)mbn cells, which had been treated with double-stranded RNA (*dsRNA*) containing sequences of mRNA of the indicated genes, were analyzed for the phagocytosis of apoptotic S2 cells as in *A* (*top*) as well as for the level of mRNA of the indicated genes by RT-PCR (*bottom*). In the *top panel*, data from one of three independent experiments with similar results are presented (S.D. are from data with six microscopic fields). *drpr*, *draper*; *Rp*, gene coding for ribosomal protein S15Ab.

phosphorylation of FAK56 in l(2)mbn cells. To do so, the cells were maintained in culture containers coated with GST-fused proteins for 2 h, and their lysates were analyzed by Western blotting for the levels of phosphorylated and total FAK56. We found that the incubation of cells with either Trol protein resulted in a slight (1.2–1.5-fold) but reproducible increase in the level of phosphorylated FAK56, leaving the total amount of FAK56 unchanged (Fig. 2*B*, *bottom panels*). These results suggested that Trol, likely through the RGD motif, activates integrin in l(2)mbn cells.We next extended the analysis of integrin to examine its role in the phagocytosis of apoptotic cells in *Drosophila*.

Integrin is a heterodimer of  $\alpha$  and  $\beta$  subunits, both of which are single-path membrane proteins (33). There exist five  $\alpha$  and two  $\beta$  subunits for the *Drosophila* integrin (34), and we began by searching for the  $\beta$  subunit,  $\beta\nu$  or  $\beta$ PS, involved in the phagocytosis of apoptotic cells. We analyzed two mutant alleles of *betaInt-nu* coding for β*v* as well as of *myospheroid* (*mys*) coding for PS. It was already known that either *mys* allele is null for

the expression of integrin BPS (23), but the level of integrin  $\beta\nu$ expression needed to be determined for the two *betaInt-nu* alleles. To do so, we generated an anti-integrin  $\beta\nu$  antibody and analyzed lysates of *Drosophila* larvae by Western blotting. The  $\beta\nu$  subunit appeared as a signal with a molecular mass of about 110 kDa in the lysate of *w<sup>1118</sup>* flies but was undetectable in the two mutants (Fig. 2*C*), indicating that each *betaInt-nu* allele is null for integrin  $\beta\nu$  expression. We then determined the level of phagocytosis in embryos of mutant flies lacking  $\beta\nu$  or  $\beta$ PS. The level in the  $\beta\nu$  mutants was decreased, whereas that in the  $\beta\mathrm{PS}$ mutants was almost the same as in embryos of control  $w^{1118}$ flies (Fig. 2*D*, *top panel*). The reduction in phagocytosis in embryos of the  $\beta\nu$  mutants seemed not to be due to a change in the level of hemocytes or apoptosis because the numbers of hemocytes and apoptotic cells relative to all dispersed cells remained unaltered in the mutant animals (Fig. 2*D*, *middle* and *bottom panels*).

Independent Actions of Integrin βv and Draper in Hemocytes— Integrin  $\beta\nu$  appeared to be continuously expressed in  $w^{1118}$  flies





FIGURE 2.**Identification of integrin**- **required for the phagocytosis of apoptotic cells in** *Drosophila* embryos. A, the structure of Trol (a product from transcript variant C) is schematically exhibited with the positions of the motif RGD. Shown below are portions of Trol prepared as recombinant proteins fused to GST (*GST-Trol 1* and*GST-Trol 2*). The numbers are amino acid positions with the amino terminus numbered 1. *B*, *top*, l(2)mbn cells that had been incubated with the indicated proteins were immunocytochemically analyzed for the bound proteins using anti-GST antibody. Phase-contrast and fluorescence micrographs of the same fields are shown. The *arrowheads* point to the positive signals. *Scale bar*, 10  $\mu$ m. Bottom, lysates (20  $\mu$ g of protein) of l(2)mbn cells that had been incubated in culture containers coated with the indicated proteins were analyzed by Western blotting with the anti-phospho-FAK antibody and anti-FAk56 antibody. The *arrowheads*indicate the positions of phosphorylatedFAK56and totalFAK56.The intensity of the signals was determined, and averages from three independent experiments are shown relative to the result with a negative control (*GST*). *C*, lysates (0.13 mg of protein) of larvae of the indicatedfly lines were analyzed by Western blotting with the anti-integrin  $\beta\nu$  antibody. The *arrowhead* indicates the position of integrin  $\beta \nu$ . D, dispersed embryonic cells of the indicated fly lines were analyzed for the phagocytosis of apoptotic cells by hemocytes (*top*), the population ofhemocytes(*middle*),and thenumber ofapoptoticcells(*bottom*).The ratios in percentage terms of hemocytes that had accomplished phagocytosis (*top*), of hemocytes to all embryonic cells (*middle*), and of apoptotic cells to all embryonic cells (*bottom*) are shown. Genotypes of the fly lines analyzed are *w*; betaInt-nu<sup>1</sup> (*betaInt-nu1* ), *w; betaInt-nu2* (*betaInt-nu2* ), *mys1 /Y* (*mys1* ), and *sn mysXG43/Y* (*mysXG43*). Significance is *versus w1118*.

throughout the developmental process, as is Draper (18), and its level was higher in embryos and lower in pupae (Fig. 3*A*). We next immunocytochemically examined the presence of integrin  $\beta\nu$  at the surface of hemocytes. When l(2)mbn cells were analyzed under conditions without membrane permeabilization, punctate signals were seen with the anti-integrin  $\beta\nu$  antibody but not with the preimmune rat serum (Fig. 3*B*, *left panels*). These signals almost disappeared when the analysis was done in the presence of the corresponding antigen protein but not in the presence of a protein used as a negative control [\(supple](http://www.jbc.org/cgi/content/full/M110.204503/DC1)[mental Fig. 1](http://www.jbc.org/cgi/content/full/M110.204503/DC1)*C*), indicating the specificity of the antibody used. We then similarly analyzed dispersed embryonic cells of a fly line where GFP was expressed under the promoter of *serpent* that codes for a hemocyte-specific protein called Serpent and found the presence of integrin  $\beta\nu$  as patches at the surface of GFP-positive cells (Fig. 3*B*, *right panels*). These results suggested that integrin  $\beta\nu$  plays a role at the surface of hemocytes, most likely as a receptor for phagocytosis. To further examine this, we overexpressed integrin  $\beta\nu$  in hemocytes of a null mutant and found that the phagocytosis almost completely recovered (Fig. 3*C*). These results collectively suggested that integrin  $\beta\nu$  functions in embryonic hemocytes, most probably as a receptor, to achieve the effective phagocytosis of apoptotic cells.

We previously identified Draper, a *Drosophila* homologue of the *C. elegans* phagocytosis receptor CED-1, as a receptor required for the phagocytosis of apoptotic cells by hemocytes and glia in embryos (13). The relationship between integrin  $\beta\nu$ and Draper was examined next. Flies lacking either integrin  $\beta\nu$ or Draper showed almost the same level of phagocytosis, which was about two-thirds of that in control *w<sup>1118</sup>* (Fig. 4*A*). We then analyzed a double null mutant and found that the simultaneous loss of these two receptors further decreased phagocytosis, down to about one-third of the control level (Fig. 4*A*). These results suggested that integrin  $\beta\nu$  and Draper act independently, rather than activating the same signaling pathway, in the phagocytosis of apoptotic cells in *Drosophila* embryos. Draper was shown to lie upstream of CED-6 and CED-10 (18), one of the two partly overlapping pathways for phagocytosis originally found in *C. elegans*. It is therefore likely that integrin  $\beta\nu$  resides the furthest upstream of the other engulfment pathway CED-2-CED-5-CED-12 in *C. elegans*. We previously showed that hemocytes lacking Elmo, a *Drosophila* counterpart of CED-12, normally phagocytose apoptotic cells (18). We thus examined the involvement of Crk and Mbc, *Drosophila* homologues of *C. elegans* CED-2 and CED-5, respectively, in the integrin  $\beta\nu$ -mediated phagocytosis. When embryos of fly lines in which RNAi for *Crk* and *mbc* was induced in hemocytes were analyzed, the level of phagocytosis of apoptotic cells was almost equal to that in embryos of a control fly line [\(supplemental Fig.](http://www.jbc.org/cgi/content/full/M110.204503/DC1) [3\)](http://www.jbc.org/cgi/content/full/M110.204503/DC1). Inhibition of the expression of Crk and Mbc in the RNAiinduced hemocytes seemed likely because the same fly lines barely developed into adults after induction of RNAi in all cell types [\(supplemental Table 1\)](http://www.jbc.org/cgi/content/full/M110.204503/DC1), as reported previously for null mutants of *Crk* (35) and *mbc* (36). These results indicate that Crk and Mbc do not seem to participate in the phagocytosis of apoptotic cells at least by embryonic hemocytes. Consequently, the existence of the pathway Crk-Mbc-Elmo downstream of



FIGURE 3. Presence and function of integrin  $\beta\nu$  in hemocytes. A, lysates (0.1 mg of protein) of  $w^{1118}$  flies at the indicated developmental stages were analyzed by Western blotting with the anti-integrin  $\beta\nu$  antibody. The *arrowhead* points to the position of integrin  $\beta\nu$ . B, I(2)mbn cells (left) and dispersed embryonic cells of *y w; srpHemo-GAL4 UAS-srcEGFP f*lies (*right*) were subjected to immunocytochemistry with the anti-integrin βν antibody or preimmune rat serum as a negative control under membrane-nonpermeabilizing conditions. Embryonic hemocytes were identified based on the expression of GFP driven by the promoter of *serpent*. Note that most GFP-positive cells were also positive for the expression of Croquemort (data not shown). Phase-contrast and fluorescence micrographs of the same fields are shown. The *arrowheads* point to the signals derived from the anti-integrin βνantibody. Scale bars, 10 μm. C, dispersed embryonic cells of the indicated flies were analyzed for the phagocytosis of apoptotic cells by hemocytes. The ratio of hemocytes that had accomplished phagocytosis to total hemocytes is shown. Genotypes of the fly lines analyzed are *w; betaInt-nu<sup>2</sup>* (*betaInt-nu2* GAL4 UAS), *w; betaInt-nu2* /*betaInt-nu2 srpHemoGAL4 UAS-srcEGFP* (*betaInt-nu2*GAL4 UAS), *w; betaInt-nu2 ; UAS-betaInt-nu/* (*betaInt-nu2*GAL4 UAS), and *w; betaInt-nu2* /*betaInt-nu2 srpHemo-GAL4 UAS-srcEGFP; UAS-betaInt-nu/+ (betaInt-nu<sup>2</sup> GAL4+ UAS+).* 



FIGURE 4. Independent actions of integrin  $\beta\nu$  and Draper. A, dispersed embryonic cells of the indicated flies were analyzed for the phagocytosis of apoptotic cells by hemocytes. The ratio of hemocytes that had accomplished phagocytosis to total hemocytes is shown. *B*, periods in the development of *Drosophila* from embryos to adults were determined with the indicated fly lines. Genotypes of the fly lines analyzed are *w; betaInt-nu<sup>2</sup> (betaInt-nu<sup>2</sup>), w; + ;<br>drpr<sup>∆s</sup> (drpr<sup>∆s</sup>), and <i>w; betaInt-nu<sup>2</sup>; drpr<sup>∆s</sup> (betaInt-nu<sup>2</sup> drpr<sup>∆s</sup>).* 

integrin  $\beta\nu$  remained uncertain. Finally, flies lacking these two major receptors for the phagocytosis of apoptotic cells did not show a crucial defect in development but took longer to develop into adults than *w<sup>1118</sup>* or each single mutant (Fig. 4*B*).

#### **DISCUSSION**

In the present study, we identified Trol, a core protein of proteoglycan, and integrin  $\beta\nu$ , a  $\beta$  subunit of integrin, as components required for *Drosophila* phagocytes to achieve effective phagocytosis of apoptotic cells. The involvement of integrin in the phagocytosis of apoptotic cells has been known for mam-

mals; integrins  $\alpha_{\rm v}\beta_3$  and  $\alpha_{\rm v}\beta_5$  serve as a receptor for milk fat globule EGF factor 8, which binds on one side to integrin via the RGD motif and on the other side to phosphatidylserine exposed at the surface of apoptotic cells (37). Trol or Trol-containing proteoglycan might serve to connect apoptotic cells and *Drosophila* hemocytes, although the binding of Trol to apoptotic cells remains to be shown. Recently, INA-1, an  $\alpha$  subunit of *C. elegans* integrin, was reported to be responsible for the phagocytosis of cell corpses (17). It is thus most probable that integrin is an evolutionally conserved receptor for the phagocytosis of apoptotic cells, and our finding has filled in a blank for insects.

The two partly overlapping pathways for the induction of phagocytosis in *C. elegans* are presumably conserved among species (9, 38). Mammalian integrin  $\alpha_{\rm v}\beta_5$  (39) and nematode INA-1 (17) were shown to connect with a pathway consisting of CrkII-DOCK180-ELMO-Rac1 for mammals and CED-2-CED-5-CED-12-CED-10 for *C. elegans*. Our data indicated an independent action of integrin  $\beta\nu$  from Draper that activates the pathway Ced-6-Rac1/Rac2 corresponding to CED-6-CED-10 of *C. elegans* (18), suggesting that integrin  $\beta \nu$  is located upstream of the other pathway. However, it is unclear whether a presumed pathway in *Drosophila*, Crk-Mbc-Elmo-Rac1/ Rac2, lies downstream of integrin  $\beta\nu$  because the involvement of this pathway itself in the phagocytosis by *Drosophila* phagocytes still remains ambiguous. The situation becomes more complicated when we consider how phagocytes recognize apoptotic cells through the actions of the two presumed receptors. In mammals, milk fat globule EGF factor 8 is simultaneously bound by integrin and phosphatidylserine to connect phagocytes and apoptotic cells. A similar bridging protein was recently found in *C. elegans* (40). This protein, called TTR-52, binds to phosphatidylserine but seemingly serves as a ligand for CED-1, not INA-1. In addition, phosphatidylserine-binding



phagocytosis receptors in mammals seem to activate either of the two conserved pathways (41, 42). It is thus likely that utilization of the two pathways is defined not by markers but by receptors for phagocytosis. On the other hand, the binding of Trol seemed to activate integrin and increase the level of FAK phosphorylation. The requirement of FAK has been shown for mammals in the integrin  $\alpha_{\rm v}\beta_5$ -mediated phagocytosis of apoptotic cells (43) or spent photoreceptor outer segment fragments (44) and for insects in the integrin-mediated phagocytosis of bacteria (45). Therefore, it is possible that phosphorylated FAK is included in a signaling pathway activated by integrin  $\beta \nu$ , although INA-1 does not seem to need FAK to induce phagocytosis (17). The intracellular region of  $\beta$  subunits contains the amino acid sequence NP*X*Y that is bound by the cytoskeleton protein talin (46), and this binding is believed essential for the activation of integrin. It is therefore worth knowing whether talin interacts with signal mediators of the engulfment pathways, although there is a report that the activation of integrin  $\beta_5$ in the phagocytosis of apoptotic cells occurs independent of the NP*X*Y motif (47).

More issues remain to be clarified regarding how integrin  $\beta\nu$ acts to induce the phagocytosis of apoptotic cells by *Drosophila* hemocytes. A Trol protein containing the RGD motif bound to the surface of l(2)mbn cells (Fig. 2*B*), but direct interaction between this protein and a protein corresponding to the extracellular region of integrin  $\beta \nu$  was not observed (data not shown). This suggests that integrin  $\beta\nu$  needs to form a heterodimer with an  $\alpha$  subunit to bind Trol. It is necessary to find which of five *Drosophila*  $\alpha$  subunits forms a complex and cooperates with integrin  $\beta \nu$ . In addition, the fact that a significant level of phagocytosis exists in embryos lacking both Draper and integrin  $\beta\nu$  indicates the presence of other mechanisms for the phagocytosis of apoptotic cells in *Drosophila*. Finally, our data showed that a loss of both Draper and integrin  $\beta\nu$  caused a delay in eclosion. This suggests the involvement of the phagocytic removal of apoptotic cells in the development of *Drosophila*.

*Acknowledgments—We thank Danny Brower, Nicholas Brown, Marc* Freeman, Herbert Jäckle, Nobert Perrimon, the Bloomington Dro*sophila Stock Center, the Vienna Drosophila RNAi Center, and the DGRC for fly stocks and the National Institute of Genetics for EST clones. We are grateful to Takayuki Kuraishi for suggestions and Kunizo Arai for contributing to our study at the initial stage. We also acknowledge the use of FlyBase.*

#### **REFERENCES**

- 1. Savill, J., and Fadok, V. (2000) *Nature* **407,** 784–788
- 2. Liao, D. J. (2005) *Med. Hypotheses* **65,** 23–28
- 3. Nakanishi, Y., Nagaosa, K., and Shiratsuchi, A. (2011) *Dev. Growth Differ.* **53,** 149–160
- 4. Lauber, K., Blumenthal, S. G., Waibel, M., and Wesselborg, S. (2004) *Mol. Cell* **14,** 277–287
- 5. Ravichandran, K. S., and Lorenz, U. (2007) *Nat. Rev. Immunol.* **7,** 964–974
- 6. Reddien, P. W., and Horvitz, H. R. (2004) *Annu. Rev. Cell Dev. Biol.* **20,** 193–221
- 7. Kinchen, J. M., and Hengartner, M. O. (2005) *Curr. Top. Dev. Biol.* **65,**  $1 - 45$
- 8. Mangahas, P. M., and Zhou, Z. (2005) *Semin. Cell Dev. Biol.* **16,**

295–306

- 9. Lettre, G., and Hengartner, M. O. (2006) *Nat. Rev. Mol. Cell Biol.* **7,** 97–108
- 10. Zhou, Z., Hartwieg, E., and Horvitz, H. R. (2001) *Cell* **104,** 43–56
- 11. Callebaut, I., Mignotte, V., Souchet, M., and Mornon, J. P. (2003) *Biochem. Biophys. Res. Commun.* **300,** 619–623
- 12. Freeman, M. R., Delrow, J., Kim, J., Johnson, E., and Doe, C. Q. (2003) *Neuron* **38,** 567–580
- 13. Manaka, J., Kuraishi, T., Shiratsuchi, A., Nakai, Y., Higashida, H., Henson, P., and Nakanishi, Y. (2004) *J. Biol. Chem.* **279,** 48466–48476
- 14. Wu, H. H., Bellmunt, E., Scheib, J. L., Venegas, V., Burkert, C., Reichardt, L. F., Zhou, Z., Fariñas, I., and Carter, B. D. (2009) *Nat. Neurosci*. 12, 1534–1541
- 15. Hamon, Y., Trompier, D., Ma, Z., Venegas, V., Pophillat, M., Mignotte, V., Zhou, Z., and Chimini, G. (2006) *PLoS ONE* **1,** e120
- 16. Cabello, J., Neukomm, L. J., Günesdogan, U., Burkart, K., Charette, S. J., Lochnit, G., Hengartner, M. O., and Schnabel, R. (2010) *PLoS Biol.* **8,** e1000297
- 17. Hsu, T. Y., and Wu, Y. C. (2010) *Curr. Biol.* **20,** 477–486
- 18. Kuraishi, T., Nakagawa, Y., Nagaosa, K., Hashimoto, Y., Ishimoto, T., Moki, T., Fujita, Y., Nakayama, H., Dohmae, N., Shiratsuchi, A., Yamamoto, N., Ueda, K., Yamaguchi, M., Awasaki, T., and Nakanishi, Y. (2009) *EMBO J.* **28,** 3868–3878
- 19. Franc, N. C., Dimarcq, J. L., Lagueux, M., Hoffmann, J., and Ezekowitz, R. A. (1996) *Immunity* **4,** 431–443
- 20. Franc, N. C., Heitzler, P., Ezekowitz, R. A., and White, K. (1999) *Science* **284,** 1991–1994
- 21. Kurucz, E., Zettervall, C. J., Sinka, R., Vilmos, P., Pivarcsi, A., Ekengren, S., Hegedüs, Z., Ando, I., and Hultmark, D. (2003) Proc. Natl. Acad. Sci. U.S.A. **100,** 2622–2627
- 22. Voigt, A., Pflanz, R., Schäfer, U., and Jäckle, H. (2002) *Dev. Dyn.* 224, 403–412
- 23. Bunch, T. A., Salatino, R., Engelsgjerd, M. C., Mukai, L., West, R. F., and Brower, D. L. (1992) *Genetics* **132,** 519–528
- 24. Devenport, D., and Brown, N. H. (2004) *Development* **131,** 5405–5415
- 25. Brückner, K., Kockel, L., Duchek, P., Luque, C. M., Rørth, P., and Perrimon, N. (2004) *Dev. Cell* **7,** 73–84
- 26. Brand, A. H., and Perrimon, N. (1993) *Development* **118,** 401–415
- 27. Iozzo, R. V., Cohen, I. R., Grässel, S., and Murdoch, A. D. (1994) *Biochem*. *J.* **302,** 625–639
- 28. Brown, N. H. (2000) *Matrix Biol.* **19,** 191–201
- 29. Legate, K. R., Wickström, S. A., and Fässler, R. (2009) *Genes Dev.* 23, 397–418
- 30. Fujimoto, J., Sawamoto, K., Okabe, M., Takagi, Y., Tezuka, T., Yoshikawa, S., Ryo, H., Okano, H., and Yamamoto, T. (1999) *J. Biol. Chem.* **274,** 29196–29201
- 31. Fox, G. L., Rebay, I., and Hynes, R. O. (1999) *Proc. Natl. Acad. Sci. U.S.A.* **96,** 14978–14983
- 32. Palmer, R. H., Fessler, L. I., Edeen, P. T., Madigan, S. J., McKeown, M., and Hunter, T. (1999) *J. Biol. Chem.* **274,** 35621–35629
- 33. Shattil, S. J., Kim, C., and Ginsberg, M. H. (2010) *Nat. Rev. Mol. Cell Biol.* **11,** 288–300
- 34. Brown, N. H., Gregory, S. L., and Martin-Bermudo, M. D. (2000) *Dev. Biol.* **223,** 1–16
- 35. Ishimaru, S., Ueda, R., Hinohara, Y., Ohtani, M., and Hanafusa, H. (2004) *EMBO J.* **23,** 3984–3994
- 36. Nolan, K. M., Barrett, K., Lu, Y., Hu, K. Q., Vincent, S., and Settleman, J. (1998) *Genes Dev.* **12,** 3337–3342
- 37. Hanayama, R., Tanaka, M., Miwa, K., Shinohara, A., Iwamatsu, A., and Nagata, S. (2002) *Nature* **417,** 182–187
- 38. Kinchen, J. M., and Ravichandran, K. S. (2007) *J. Cell Sci.* **120,** 2143–2149
- 39. Akakura, S., Singh, S., Spataro, M., Akakura, R., Kim, J. I., Albert, M. L., and Birge, R. B. (2004) *Exp. Cell Res.* **292,** 403–416
- 40. Wang, X., Li, W., Zhao, D., Liu, B., Shi, Y., Chen, B., Yang, H., Guo, P., Geng, X., Shang, Z., Peden, E., Kage-Nakadai, E., Mitani, S., and Xue, D. (2010) *Nat. Cell Biol.* **12,** 655–664
- 41. Park, S. Y., Kang, K. B., Thapa, N., Kim, S. Y., Lee, S. J., and Kim, I. S. (2008)



*J. Biol. Chem.* **283,** 10593–10600

- 42. Park, D., Tosello-Trampont, A. C., Elliott, M. R., Lu, M., Haney, L. B., Ma, Z., Klibanov, A. L., Mandell, J. W., and Ravichandran, K. S. (2007) *Nature* **450,** 430–434
- 43. Wu, Y., Singh, S., Georgescu, M. M., and Birge, R. B. (2005) *J. Cell Sci.* **118,** 539–553
- 44. Finnemann, S. C. (2003) *EMBO J.* **22,** 4143–4154
- 45. Metheniti, A., Paraskevopoulou, N., Lambropoulou, M., and Marmaras, V. J. (2001) *FEBS Lett.* **496,** 55–59
- 46. Dupuy, A. G., and Caron, E. (2008) *J. Cell Sci.* **121,** 1773–1783
- 47. Singh, S., D'mello, V., van Bergen en Henegouwen, P., and Birge, R. B. (2007) *Biochem. Biophys. Res. Commun.* **364,** 540–548

